DNA, d(3'-amino-3'-deoxy-p-thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-hydroxy-3-((1-oxohexadecyl)amino)propyl) hydrogen phosphorothioate)
GRN163L is a novel anti-cancer drug. It has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many cancer types (including lung, breast, prostate, liver, and early stage of human breast cancer), in both cell culture systems and animal models. Study of this drug shows the its potential utility in the treatment of patients with hematologic and solid tumor malignancies.